Myocardial glucose metabolism in patients with hypertrophic cardiomyopathy: Assessment by F-18-FDG PET study

Toshihisa Ushara,* Yoshio Ishida,† Kohei Hayashida,† Tsuyoshi Shimokage,† Yoshinori Miyake,* Masayoshi Sago,* Hisashi Oka,* Seiki Nagata,** Kuniyo Miyatake†† and Tsuichiko Nishimura*†

*Department of Tracer Kinetics and Nuclear Medicine, Osaka University, Medical School
†Department of Radiology and ‡Department of Cardiology, National Cardiovascular Center

In an investigation of myocardial metabolic abnormalities in hypertrophic myocardium, the myocardial glucose metabolism was evaluated with F-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) in 32 patients with hypertrophic cardiomyopathy, and the results were compared with those in 9 patients with hypertensive heart disease. F-18-FDG PET study was performed in the fasting and glucose-loading states. The myocardial regional %dose uptake was calculated quantitatively. The average regional %dose uptake in the fasting state in the patients with asymmetric septal hypertrophy and dilated-phase hypertrophic cardiomyopathy was significantly higher than that in the patients with hypertensive heart disease (0.75 ± 0.34%, 0.65 ± 0.25%, and 0.43 ± 0.22%/100 g myocardium, respectively). In contrast, the average %dose uptake in the glucose-loading state in the patients with asymmetric septal hypertrophy and dilated-phase hypertrophic cardiomyopathy was not significantly different from that in patients with hypertensive heart disease (1.17 ± 0.49%, 0.80 ± 0.44% and 0.99 ± 0.45%, respectively). The patients with apical hypertrophy had also low %dose uptake in the fasting state (0.38 ± 0.21%) as in the hypertensive heart disease patients, so that the characteristics of asymmetric septal hypertrophy and dilated-phase hypertrophic cardiomyopathy are considered to be high FDG uptake throughout the myocardium in the fasting state. Patients with apical hypertrophy are considered to belong to other disease categories metabolically. F-18-FDG PET study is useful in the evaluation of the pathophysiologic diagnosis of patients with hypertrophic cardiomyopathy.

Key words: hypertrophic cardiomyopathy, positron emission tomography, glucose metabolism, F-18-FDG (fluorodeoxyglucose)